Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(6-hydroxy-1H-indazol-3-yL)benzene‑1,3‑diol is a synthetic small molecule belonging to the class of phenylpyrazoles and azole derivatives[1][4]. It has been studied as a ligand for the estrogen receptor and is known to bind with high affinity (IC50 ~48 nM)[1][9]. Structural studies have shown it can modulate estrogen receptor conformation in ways that may selectively influence gene expression related to inflammation[9]. Its primary use is experimental; it has not been approved for clinical use or assigned therapeutic indications. The compound is referenced in chemical databases such as ChEMBL (CHEMBL223026), PubChem (14086997), and others[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol.